With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued ...

Study findings indicated that psilocybin can reduce the symptoms of depression, with response and remission rates showing ...

It’s long past time for the industry to fully embrace the digital age. It’s fine to keep paper back-ups of data, but using ...

In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to existing or emerging treatments for ...

From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare ...

The National Institute for Public Employee Healthcare Policy attributed the importance to the rising cost of health care.

Respondents said they were concerned about their own mental health or the mental health of another person at higher rates ...

For decades, one of the main priorities of the United States healthcare system has been to develop life-saving treatments for ...

As of the writing of this column (May 1), the XBI stood at $88.30, well off of its recent recovery high of $102+ on Feb. 27, ...

The FDA first approved Ozempic, Novo Nordisk’s GLP-1 receptor agonist to improve glycemic control in adults with type 2 ...

The new care center will offer primary care services to uninsured and underinsured patients in the Wilmington, North Carolina ...

Cencora’s vice president of product management, global products & solutions Beth Riggio discusses the issues the industry ...